Faire un don
Suivez-nous sur Linked In
Suivez-nous sur Youtube

Governance 2025-2030

The governance structure comprises two committees : an Executive Committee and a Steering Committee , supported by an External Scientific Advisory Board.

Samuel Bitoun

Coordinator (PI)

Linked In AP-HP

Xavier Mariette

Vice coordinator

AP-HP

Camille Bigenwald

Vice coordinator

Linked In

Léo Plaçais

Head of Clinical Research

AP-HP

Myriam Morcel

Manager FHU

Clinical Research and Innovation Department (DRCI) of Greater Paris University Hospitals – AP-HP

Linked In

Diane Martinez

Head of the Transformation and Quality Management Department

Clinical Research and Innovation Department (DRCI) of Greater Paris University Hospitals – AP-HP

Linked In


Samuel Bitoun, MD, PhD, the project leader, has a double specialty of Rheumatology and Oncology, and defended a PhD thesis in Immunology. He served as CCA (Fellow) of the FHU CARE in 2020 and then as PHU in the immune-rheumatology department of Bicetre hospital led by Pr Xavier Mariette. Samuel Bitoun is an elected representative of assistant professor body on the board of the Paris-Saclay medical school. He is also part of a guideline committee at EULAR (European rheumatology society) that has emitted points to consider for the care of patients with Rheumatic diseases and Cancer. Finally, he is also part of the ACR (American College of Rheumatology /EULAR) classification criteria joint committee for rheumatologic Immune adverse events of immune checkpoints. He is a member of the Steering committee of the MD, PhD Averroes program which helps medical pharmacy students and scientist from any field to perform high level research in various domains ranging from mathematics to biology, law and sociology. This program allows students to have access to any course in any field available at Paris-Saclay University. Pr Xavier Mariette continue to be involved in FHU CARE² as a co-coordinator. For FHU CARE², Samuel Bitoun takes over Xavier Mariette, the creator of the FHU CARE and of the DIM ITAC (Immunotherapy, Autoimmunity and Cancer).

Executive Committee (9 members)

Leadership :

Axis Leaders :

  1. New Tools: Gaëtane Nocturne and Raphaèle Seror
  2. New Mechanisms: Camille Bigenwald
  3. New Treatments: Xavier Mariette and Samuel Bitoun
  4. New Education: Samuel Bitoun

Clinical Support:

The « Chef de Clinique » position, provided by Paris-Saclay University, is held by Léo Plaçais, whose responsibilities include:

  • Assisting with patient recruitment for ongoing clinical trials (Axis 3)
  • Coordinating patient inclusion in immunological studies (Axis 2)

Steering Committee (16 members)

Leadership team:

Clinical experts:

Researchers:

Institutional representatives:

AP-HP,INSERM,Paris-Saclay University,Institut Gustave Roussy,CEA,INRAE.

Key Responsibilities:

The Steering Committee holds strategic, financial, and managerial authority with the following core missions:

  • Approval of strategic decisions
  • Approval of annual work plans and oversight of implementation
  • Approval of annual reports and end-of-mandate evaluations
  • Decision-making regarding intellectual property of consortium discoveries

External Scientific Advisory Board (9 members)

Distinguished Members:

  • Prof. Michel Sadelain (Memorial Sloan Kettering Cancer Center) – inventor of anti-CD19 CAR-T cells
  • Prof. Antony Rosen (Johns Hopkins, Baltimore) – recognized expert in autoimmune diseases/cancer relationships
  • Prof. Len Calabrese (Cleveland Clinic) – immune-rheumatologist expert in Immune-Related Adverse Events of immune checkpoint inhibitors
  • Prof. François Ghiringhelli (Dijon University) – renowned cancer specialist

Patient association Representatives :

Industry partners:

Three representatives from pharmaceutical companies supporting the project: